Table 4.
Immunological parameters between the good responsive and poor responsive groups at the end of the 2 years following cessation of SLIT.
| Parameters | Good responsive group | Poor responsive group |
|---|---|---|
| IL-4 | 3.7 ± 1.5 | 3.1 ± 1.6 |
| IL-5 | 38.6 ± 21.2 | 40.3 ± 18.3 |
| IL-13 | 216 ± 98 | 178 ± 112 |
| IL-17 | 108 ± 56 | 123 ± 64 |
| IL-21 | 133 ± 87 | 127 ± 69 |
| IL-10 | 46.8 ± 17.6 | 22.6 ± 15.4∗ |
| TGF-beta | 97.6 ± 43.8 | 53.1 ± 22.7∗ |
| IL-35 | 316 ± 112 | 178 ± 103∗ |
| Th2% | 2.4 ± 0.9 | 2.6 ± 0.8 |
| Th17% | 0.8 ± 0.4 | 0.7 ± 0.6 |
| Tfh2% | 0.4 ± 0.2 | 0.3 ± 0.1 |
| ILC2% | 0.15 ± 0.04 | 0.13 ± 0.05 |
| Treg% | 2.3 ± 1.5 | 0.5 ± 0.2∗ |
| Breg% | 0.7 ± 0.2 | 0.1 ± 0.05∗ |
| Tfr% | 0.2 ± 0.1 | 0.08 ± 0.02∗ |
All the unit of cytokines were pg/ml; SLIT, sublingual immunotherapy, Treg, regulatory T cell, Breg, regulatory B cell, Tfr, follicular regulatory T cell, Th2, T helper 2 cell, Th17, T helper 17 cell, Tfh2, follicular T helper 2 cell, ILC2, group 2 innate lymphoid cells. The calculation of Th2, Th17, Tfh and Tfr cells percentage is based on the numbers of CD4+ T cell as the denominator. The calculation of Treg, Breg and ILC2 is based on the numbers PBMC as the denominator. ∗ Compared with Good responsive group, P < 0.05